Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy

NCT00356525 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00356525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2006
Completion date
April 30, 2009
Enrollment
41 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms